Ionis Pharmaceuticals (IONS) and Otsuka Pharmaceutical announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted an opinion of Dawnzera for the routine prevention of recurrent attacks of hereditary angioedema in adults and adolescents aged 12 years and older. The opinion is now referred to the European Commission for an approval decision.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Arrowhead price target raised to $45 from $29 at Morgan Stanley
- Ionis Pharmaceuticals announces $700M convertible senior notes offering
- Ionis Pharmaceuticals’ Olezarsen: Promising Phase 3 Results and Blockbuster Potential Justify Buy Rating
- Ionis Pharmaceuticals Reports Positive Phase 3 Study Results
- Ionis Pharmaceuticals price target raised to $110 from $100 at H.C. Wainwright